+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06812533

Evaluation of the Alleviant ALV1 System Device Procedure Compared to Sham Control in Heart Failure Patients With Reduced Ejection Fraction

Led by Alleviant Medical, Inc. · Updated on 2026-10-06

350

Participants Needed

70

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the safety and effectiveness of a new device called the Alleviant ALV1 System, designed to create an interatrial shunt for patients with heart failure and reduced ejection fraction HFrEF. This prospective, randomized, double-blind, sham-controlled trial involves multiple centers and aims to compare the outcomes of patients receiving this device to those undergoing a sham procedure. The study focuses on those with heart failure who have a left ventricular ejection fraction of 40% or less and are classified as NYHA class II, III, or ambulatory IV. Participants are randomly assigned to one of two groups. The treatment group undergoes cardiac imaging, femoral vein access, and receives the Alleviant ALV1 System device procedure to create the interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement but does not receive the device. The study uses a crossover design, allowing comparison between the treatment and sham procedures under double-blind conditions. Throughout the study, participants will be monitored for safety and efficacy, with cardiac imaging used to assess outcomes. The primary outcome is a composite endpoint measured at 12 months, which evaluates the overall impact of the device on heart failure. The trial is sponsored by Alleviant Medical, Inc. and will continue until December 2028. Participants can expect regular assessments and follow-up visits during the study period.

CONDITIONS

Brief Title

Alleviant ALLAY-HFrEF Study

Research Team

S

Stacia Kraus

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here